Exciting news awaits! Sussex Research Laboratories Inc. is poised to unveil their pioneering strides in pharmaceutical development of peptide therapeutics at the highly anticipated Boulder Peptide Symposium (BPS) 2023, set against the picturesque backdrop of Napa, California on Monday, September 18. Located at booth #9, our esteemed leadership team, including CEO Dr. Brady Clark, CSO Dr. Corwin Nycholat, COO Remmick So, and our Director of Glycopeptides, Dr. Chuda Lohani will be available to discuss our groundbreaking innovations within the realm of peptide science. BPS 2023 is renowned for its ability to congregate some of the most brilliant minds in the field, rendering it the perfect platform for Sussex Research Laboratories Inc. to spotlight their invaluable contributions to the world of peptide research. Do not miss this golden opportunity to delve into the forefront of peptide science at this prestigious event!

For over 25 years, we have enabled application of complex carbohydrate systems, including GalNAc and glycopeptides, in drug discovery, drug delivery, drug targeting, glycoconjugate vaccine development, immunotherapy, therapeutic enhancement and diagnostic/bio-analytical assay development. 

About Sussex Research Laboratories Inc.

Sussex Research Laboratories Inc. is a global leader in Carbohydrate Synthesis. We excel at translating complex carbohydrate chemistries into unique, leading-edge products that enable researchers to explore and exploit glycobiology in applications that promote human health. Our product portfolio and contract research & development services enable our clients and partners to apply discoveries in glycomics for drug development & discovery, drug delivery & targeting, vaccine development and monoclonal antibody development. Experience glyco-enhancement of your small molecule, protein, oligonucleotide or other macromolecule through Sussex Research Laboratories Inc.. We are the GalNAc, Glycan, Ligand, Glycopeptide and Glycoconjugate Specialists.